PCYT2 deficiency in Saarlooswolfdogs with progressive retinal, central, and peripheral neurodegeneration.

Animal model Canis lupus familiaris Inborn error of metabolism Kennedy pathway Neurology Ophthalmology Precision medicine

Journal

Molecular genetics and metabolism
ISSN: 1096-7206
Titre abrégé: Mol Genet Metab
Pays: United States
ID NLM: 9805456

Informations de publication

Date de publication:
21 Jan 2024
Historique:
received: 19 12 2023
revised: 19 01 2024
accepted: 19 01 2024
medline: 27 1 2024
pubmed: 27 1 2024
entrez: 26 1 2024
Statut: aheadofprint

Résumé

We investigated a syndromic disease comprising blindness and neurodegeneration in 11 Saarlooswolfdogs. Clinical signs involved early adult onset retinal degeneration and adult-onset neurological deficits including gait abnormalities, hind limb weakness, tremors, ataxia, cognitive decline and behavioral changes such as aggression towards the owner. Histopathology in one affected dog demonstrated cataract, retinal degeneration, central and peripheral axonal degeneration, and severe astroglial hypertrophy and hyperplasia in the central nervous system. Pedigrees indicated autosomal recessive inheritance. We mapped the suspected genetic defect to a 15 Mb critical interval by combined linkage and autozygosity analysis. Whole genome sequencing revealed a private homozygous missense variant, PCYT2:c.4A>G, predicted to change the second amino acid of the encoded ethanolamine-phosphate cytidylyltransferase 2, XP_038402224.1:(p.Ile2Val). Genotyping of additional Saarlooswolfdogs confirmed the homozygous genotype in all eleven affected dogs and demonstrated an allele frequency of 9.9% in the population. This experiment also identified three additional homozygous mutant young dogs without overt clinical signs. Subsequent examination of one of these dogs revealed early-stage progressive retinal atrophy (PRA) and expansion of subarachnoid CSF spaces in MRI. Dogs homozygous for the pathogenic variant showed ether lipid accumulation, confirming a functional PCYT2 deficiency. The clinical and metabolic phenotype in affected dogs shows some parallels with human patients, in whom PCYT2 variants lead to a rare form of spastic paraplegia or axonal motor and sensory polyneuropathy. Our results demonstrate that PCYT2:c.4A>G in dogs cause PCYT2 deficiency. This canine model with histopathologically documented retinal, central, and peripheral neurodegeneration further deepens the knowledge of PCYT2 deficiency.

Identifiants

pubmed: 38277988
pii: S1096-7192(24)00034-9
doi: 10.1016/j.ymgme.2024.108149
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

108149

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest A.K. is an employee of Laboklin, a veterinary diagnostic laboratory that offers genetic testing for animals.

Auteurs

Matthias Christen (M)

Institute of Genetics, Vetsuisse Faculty, University of Bern, Bern 3001, Switzerland.

Anna Oevermann (A)

Division of Neurological Sciences, Vetsuisse Faculty, University of Bern, Bern 3001, Switzerland.

Stefan Rupp (S)

Neurology Department, Tierklinik Hofheim, IVC Evidensia, Hofheim am Taunus 65719, Germany.

Frédéric M Vaz (FM)

Amsterdam UMC, University of Amsterdam, Department of Clinical Chemistry and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Inborn Errors of Metabolism, Amsterdam, the Netherlands; Core Facility Metabolomics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

Eric J M Wever (EJM)

Amsterdam UMC, University of Amsterdam, Department of Clinical Chemistry and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Meibergdreef 9, Amsterdam, the Netherlands; Amsterdam Gastroenterology Endocrinology Metabolism, Inborn Errors of Metabolism, Amsterdam, the Netherlands; Core Facility Metabolomics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Bioinformatics Laboratory, Department of Epidemiology & Data Science, Amsterdam Public Health Research Institute, University of Amsterdam, 1100 DE Amsterdam UMC, the Netherlands.

Barbara K Braus (BK)

Ophthalmology Department, Tierklinik Hofheim, IVC Evidensia, Hofheim am Taunus 65719, Germany.

Vidhya Jagannathan (V)

Institute of Genetics, Vetsuisse Faculty, University of Bern, Bern 3001, Switzerland.

Alexandra Kehl (A)

Laboklin GmbH & Co. KG, Steubenstraße 4, Bad Kissingen 97688, Germany; Comparative Experimental Pathology, School of Medicine, Technical University of Munich (TUM), Munich, Germany.

Marjo K Hytönen (MK)

Department of Medical and Clinical Genetics, University of Helsinki, Helsinki 00014, Finland; Department of Veterinary Biosciences, University of Helsinki, Helsinki 00014, Finland; Folkhälsan Research Center, Helsinki 00290, Finland.

Hannes Lohi (H)

Department of Medical and Clinical Genetics, University of Helsinki, Helsinki 00014, Finland; Department of Veterinary Biosciences, University of Helsinki, Helsinki 00014, Finland; Folkhälsan Research Center, Helsinki 00290, Finland.

Tosso Leeb (T)

Institute of Genetics, Vetsuisse Faculty, University of Bern, Bern 3001, Switzerland. Electronic address: tosso.leeb@unibe.ch.

Classifications MeSH